Atara Biotherapeutics
ATRA • NASDAQ
Atara Biotherapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Anhco Nguyen, with a market cap of $37.5M.
CEOAnhco Nguyen
Next Earnings
Upcoming earnings announcement for Atara Biotherapeutics
Date
Thursday, May 14, 2026 (in a month)
Timing
Before Market Open (8:00 AM New York)
Fiscal Period
Q1 2026
EPS Estimate
$0.71
Revenue Estimate
$850.0K
Earnings History
Past 12 earnings reports for Atara Biotherapeutics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 16, 2026 | Q4 2025 | -$0.25Est: -$0.07 | -257.1% | $1.6MEst: $1.6M | -2.3% |  10-K |
| Nov 12, 2025 | Q3 2025 | -$0.32Est: -$0.73 | +56.2% | $3.5MEst: $2.2M | +59.9% | 10-Q |
| Aug 11, 2025 | Q2 2025 | $0.19Est: -$0.32 | +159.4% | $17.6MEst: $5.6M | +215.7% | 10-Q |
| May 15, 2025 | Q1 2025 | $3.50Est: -$1.92 | +282.3% | $98.1MEst: $4.3M | +2182.5% | 10-Q |
| Mar 7, 2025 | Q4 2024 | -$1.19Est: -$2.48 | +52.0% | $32.8MEst: $24.8M | +32.3% | 10-K |
| Nov 12, 2024 | Q3 2024 | -$2.93Est: -$1.93 | -51.8% | $40.2MEst: $35.2M | +14.3% | 10-Q |
| Aug 12, 2024 | Q2 2024 | -$3.10Est: -$1.56 | -98.7% | $28.6MEst: $40.0M | -28.4% | 10-Q |
| May 9, 2024 | Q1 2024 | -$5.75Est: -$6.50 | +11.5% | $27.4MEst: $24.7M | +10.8% | 10-Q |
| Mar 28, 2024 | Q4 2023 | -$14.00Est: -$12.00 | -16.7% | $4.3MEst: $11.6M | -63.2% | 10-K |
| Nov 1, 2023 | Q3 2023 | -$16.50Est: -$16.50 | 0.0% | $2.1MEst: $4.8M | -55.1% | — |
| Aug 8, 2023 | Q2 2023 | -$17.00Est: -$16.75 | -1.5% | $957.0KEst: $3.8M | -74.6% | 10-Q |
| May 8, 2023 | Q1 2023 | -$18.00Est: -$9.75 | -84.6% | $1.2MEst: $30.7M | -96.0% | — |